21526 ⎘
Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds; Lipids, e.g. triglycerides; Polycationic carriers Phospholipids
RADIOLABELED LIPOSOMES AND METHODS OF USE FOR TREATING LEPTOMENINGEAL METASTASES
#2METHODS FOR INHIBITING TRAINED IMMUNITY WITH NANOBIOLOGIC COMPOSITIONS
#3Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#4TREATMENT OF CANCERS WITH A REGIMEN OF TARGETED RADIONUCLIDE THERAPY AND DUAL CAR T CELL THERAPY
#5Radiohalogenated Agents for in Situ Immune Modulated Cancer Vaccination
#6GLUTAMINASE INHIBITOR THERAPY
#7Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination
#8Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#9PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT
#10ADHESIVE/ADSORPTION SWITCH ON NANOPARTICLES TO INCREASE TUMOR UPTAKE AND DELAY TUMOR CLEARANCE
#11Macrocyclic Agents for Targeted Dual-Modality PET and MRI Imaging of Cancer
#12METHODS FOR TREATING CANCER
#13Glutaminase inhibitor therapy
#14Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of Cancer
#15NANOBIOLOGIC COMPOSITIONS FOR INHIBITING TRAINED IMMUNITY
#16Glutaminase inhibitor therapy
#17Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
#18Radiohalogenated agents for in situ immune modulated cancer vaccination
#19Macrocyclic Agents for Targeted Dual-Modality PET and MRI Imaging of Cancer
#20IMAGING OF TUMOR-ASSOCIATED MACROPHAGES
#21Glutaminase inhibitor therapy
#22RECEPTOR-BINDING DOMAINS LIGANDS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF PANCREATIC CANCER
#23IMAGING OF TUMOR-ASSOCIATED MACROPHAGES
#24Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
#25Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
#26Radiohalogenated agents for in situ immune modulated cancer vaccination
#27Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression
#28Gadolinium expressed lipid nanoparticles for magnetic resonance imaging
#29Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer
#30Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression
#31Phospholipid analogs as diapeutic agents and methods thereof
#32Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
#33In vivo methods of monitoring biodistribution
#34Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
#35Phospholipid analogs as diapeutic agents and methods thereof
#36Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer
#37Entrapment of radionuclides in nanoparticle compositions
#38Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression
#39NON-RADIOACTIVE PHOSPHOLIPID COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
#40GADOLINIUM EXPRESSED LIPID NANOPARTICLES FOR MAGNETIC RESONANCE IMAGING
#41NON-RADIOACTIVE PHOSPHOLIPID COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
#42ETHER AND ALKYL PHOSPHOLIPID COMPOUNDS FOR TREATING CANCER AND IMAGING AND DETECTION OF CANCER STEM CELLS
#43Multi-subunit biological complexes for treatment of plaque-associated diseases
#44Near infrared-fluorescence using phospholipid ether analog dyes in endoscopic applications
#45Virtual colonoscopy with radiolabeled phospholipid ether analogs
#46Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
#47Methods of detecting breast cancer, brain cancer, and pancreatic cancer
#48Virtual colonoscopy with radiolabeled phospholipid ether analogs
#49Phospholipid analogs as diapeutic* agents and methods thereof
#50Enhanced drug delivery